

PRODUCT MONOGRAPH

VAXIGRIP®

Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion)

Suspension for Injection

Active Immunizing Agent for the Prevention of Influenza

ATC Code: J07B B

Manufactured by:
Sanofi Pasteur SA
Lyon, France

Distributed by:
Sanofi Pasteur Limited
Toronto, Ontario, Canada

Date of Approval:
August 2006

Table of Contents

PART I: HEALTH PROFESSIONAL INFORMATION	4
SUMMARY PRODUCT INFORMATION	4
DESCRIPTION.....	4
INDICATIONS AND CLINICAL USE.....	4
Persons at high risk of influenza-related complications.....	5
Persons Capable of Transmitting Influenza to Those at High Risk.....	5
Immunization of Healthy Persons	6
CONTRAINDICATIONS.....	7
WARNINGS AND PRECAUTIONS	7
General	7
Hematologic	8
Immune	8
Respiratory	8
Special Populations	9
ADVERSE REACTIONS.....	9
Adverse Drug Reaction Overview	9
Clinical Trial Adverse Drug Reactions	10
Post-Market Adverse Drug Reactions.....	11
Additional Adverse Reactions.....	12
DRUG INTERACTIONS.....	14
Simultaneous Administration of Other Vaccines.....	14
DOSAGE AND ADMINISTRATION	14
Recommended Dose	14
OVERDOSAGE.....	15
ACTION AND CLINICAL PHARMACOLOGY	16
Mechanism of Action	16
Pharmacodynamics.....	16
Pharmacokinetics	16
Duration of Effect.....	16

STORAGE AND STABILITY	16
SPECIAL HANDLING INSTRUCTIONS.....	16
DOSAGE FORMS, COMPOSITION AND PACKAGING	17
Dosage Forms	17
Composition	17
PART II: SCIENTIFIC INFORMATION.....	19
PHARMACEUTICAL INFORMATION	19
Drug Substance.....	19
Product Characteristics	19
CLINICAL TRIALS	20
Study Demographics and Trial Design	20
Study Results	20
DETAILED PHARMACOLOGY.....	20
TOXICOLOGY	22
REFERENCE LIST.....	23
PART III: CONSUMER INFORMATION	26
ABOUT THIS MEDICATION.....	26
INTERACTIONS WITH THIS MEDICATION.....	27
PROPER USE OF THIS MEDICATION	27
SIDE EFFECTS AND WHAT TO DO ABOUT THEM	27

VAXIGRIP®

Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion)

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

Route of Administration	Dosage Form / Strength	Clinically Relevant Nonmedicinal Ingredients
Intramuscular injection.	<p>Suspension for injection.</p> <p>Each 0.5 mL dose is formulated to contain: 15 µg of hemagglutinin (HA) for each strain</p> <p>Each 0.25 mL dose is formulated to contain: 7.5 µg of hemagglutinin (HA) for each strain listed above.</p> <p><i>For a complete listing see DOSAGE FORMS, COMPOSITION AND PACKAGING section.</i></p>	<p>thimerosal*</p> <p>formaldehyde</p> <p>Triton® X-100†</p> <p>neomycin</p>

* in multidose presentation only

† Triton® X-100 – a registered trademark of Union Carbide, Co

DESCRIPTION

VAXIGRIP® [Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion)] for intramuscular use, is a sterile suspension containing 3 strains of influenza virus cultivated on embryonated eggs, concentrated, purified by zonal centrifugation in a sucrose gradient, split by Triton® X-100, inactivated by formaldehyde and then diluted in phosphate buffered saline solution. The type and amount of viral antigens contained in VAXIGRIP® conform to the current requirements of the World Health Organization (WHO). (1) The strains for the 2006-2007 season are A/New Caledonia/20/99 (H1N1)-like strain (A/New Caledonia/20/99 IVR-116), A/Wisconsin/67/2005 (H3N2)-like strain (A/Wisconsin/67/2005 NYMC X-161 or X-161B), B/Malaysia/2506/2004-like strain (B/Malaysia/2506/2004).

INDICATIONS AND CLINICAL USE

VAXIGRIP® [Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion)] is indicated for active immunization against influenza caused by influenza virus in adults and children 6 months of age and older.

Influenza vaccine may be administered to any child ≥ 6 months of age, adolescent, or adult in whom contraindications are not present. (2)

Although the current influenza vaccine can contain one or more of the antigens administered in previous years, annual vaccination using the current vaccine is necessary because immunity declines in the year following vaccination.

Annual influenza vaccination is particularly recommended for persons in the following categories: (2) (3)

Persons at high risk of influenza-related complications

NACI states that vaccination of persons at high risk each year before the influenza season is currently the most effective measure for reducing the impact of influenza. (2)

- **Adults and children with selected chronic health conditions** significant enough to require regular medical follow-up or hospital care, including cardiac or pulmonary disorders (including bronchopulmonary dysplasia, cystic fibrosis, and asthma), diabetes mellitus and other metabolic diseases, cancer, immunodeficiency, immunosuppression (due to underlying disease and/or therapy), renal disease, anemia or hemoglobinopathy, and conditions that compromise the management of respiratory secretions and are associated with an increased risk of aspiration. (2) Because influenza can result in serious illness and because influenza vaccination can result in the production of protective antibody titres, vaccination will benefit many HIV-infected persons, including HIV-infected pregnant women. (3)
- **Persons of any age who are residents of nursing homes and other chronic care facilities.** (2)
- **Persons 65 years of age and over.** (2) (4)
- **Children and adolescents (aged 6 months to 18 years) with conditions treated for long periods with acetylsalicylic acid.** (because of the potential increased risk of Reye syndrome associated with influenza). (2)
- **Pregnant women** with any of these co-morbidities are also at increased risk of the complications of influenza and should be immunized. (2) (See, WARNINGS AND PRECAUTIONS, Pregnant Women.)
- **Healthy children aged 6 to 23 months** are at substantially increased risk for influenza-related hospitalizations compared with healthy older children and young adults. (2) (3)

Persons capable of transmitting influenza to those at high risk

Persons who are potentially capable of transmitting influenza to those at high risk should receive annual vaccination, regardless of whether the high-risk person(s) has been immunized. (2)

- **Health care and other care providers** in facilities and community settings including regular visitors, emergency response workers, those who have contact with residents of continuing care facilities or residences, and those who provide home care for persons in high-risk groups. (2)
- Those who provide services within closed or relatively closed settings to persons at high risk (e.g., crew on ships). (2)

- **Household contacts (adults and children) of persons at high risk of influenza complications, whether or not they have been immunized.** This group includes household contacts of children < 6 months of age (who are at high risk of complications from influenza but for whom there is no available effective vaccine) and of children aged 6 to 23 months. Pregnant women should be immunized in their third trimester if they are expected to deliver during influenza season, as they will become household contacts of their newborn. (2)
- **Those providing regular child care** to children < 24 months of age whether in or out of the home. (2)
- **Persons who provide essential community services.** Vaccination for these persons should be encouraged in order to minimize the disruption of routine activities during annual epidemics. (2) (3)
- **Persons in direct contact with poultry infected with avian influenza during culling operations.** The relevant individuals include those performing the cull as well as others (such as supervising veterinarians and inspectors) who may be directly exposed to the avian virus. (2)

Immunization of healthy persons

- **Immunization of healthy persons aged 2 to 64 years.** Persons in this group should be encouraged to receive the vaccine, even if they are not in one of the aforementioned priority groups. (2)
- **Employers and their employees** should consider yearly influenza immunization for healthy working adults; as this has been shown to decrease work absenteeism from respiratory and other illnesses. (2)
- **Students or other persons in institutional settings** (e.g., those who reside in dormitories) should be encouraged to receive vaccine to minimize disruption of routine activities during epidemics. (3)
- **Travellers.** Immunization with the most current available vaccine should be offered to all travellers who wish to avoid influenza while travelling to areas where influenza is likely to be circulating. (8) Persons at high risk for complications of influenza who were not vaccinated with influenza vaccine during the preceding fall or winter should consider receiving influenza vaccine before travel if they plan to travel to the tropics, travel with organized tourist groups at any time of year, or travel to the southern hemisphere during April-September. (3)

Health care workers (HCWs) should use every opportunity to give vaccine to any person at risk who has not been immunized during the current season, even after influenza activity has been documented in the community.

Vaccine should be offered to both children and adults up to and even after influenza virus activity is documented in a community. (2) (3)

CONTRAINDICATIONS

Known systemic hypersensitivity reactions to egg proteins (egg or egg products), to chicken proteins, or any component of VAXIGRIP® [Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion)] or a life-threatening reaction after previous administration of influenza vaccine or a vaccine containing the same substances.

Vaccination must be postponed in case of febrile or acute disease.

Immunization should be delayed in a patient with an active neurologic disorder, but should be considered when the disease process has been stabilized.

The use of VAXIGRIP® in infants under 6 months of age is not recommended.

WARNINGS AND PRECAUTIONS

General

As with all products, Epinephrine Hydrochloride solution (1:1,000) and other appropriate agents should be available for immediate use in case an anaphylactic or acute hypersensitivity reaction occurs. (9) Health-care providers should be familiar with current recommendations for the initial management of anaphylaxis in non-hospital settings including proper airway management. For instructions on recognition and treatment of anaphylactic reactions see the current edition of the Canadian Immunization Guide or visit the Health Canada website.

As each dose may contain traces of formaldehyde, Triton® X-100 and undetectable traces of neomycin, which are used during vaccine production, caution should be exercised when the vaccine is administered to subjects with hypersensitivity to one of these substances or the antibiotic and the antibiotics of the same class. (See CONTRAINDICATIONS and ADVERSE REACTIONS.) (10)

The multidose vial of this vaccine contains thimerosal as a preservative. Thimerosal has been associated with allergic reactions. (11)

As with any vaccine, immunization with influenza vaccine may not protect 100% of individuals.

Influenza virus is remarkably unpredictable in that significant antigenic changes may occur from time to time. It is known that VAXIGRIP® [Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion)] as now constituted, is not effective against all possible strains of influenza virus. Protection is limited to those strains of virus from which the vaccine is prepared or against closely related strains.

The use of fractional doses in an attempt to reduce the severity of adverse reactions cannot be recommended because there is insufficient evidence on the safety or efficacy of such smaller doses. (9)

Administer the vaccine intramuscularly. VAXIGRIP® should not be administered into the buttocks due to the varying amount of fatty tissue in this region.

Do not administer by intravascular injection: ensure that the needle does not penetrate a blood vessel.

Use a separate, sterile needle and syringe or a sterile disposable unit for each individual patient to prevent disease transmission. There have been case reports of transmission of HIV and hepatitis by failure to scrupulously observe sterile technique. In particular, the same needle and/or syringe must never be used to re-enter a multidose vial to withdraw vaccine even when it is to be used for inoculation of the same patient. This may lead to contamination of the vial contents and infection of patients who subsequently receive vaccine from the vial. (12)

Before administration, take all appropriate precautions to prevent adverse reactions. This includes a review of the patient's history concerning possible hypersensitivity to the vaccine or similar vaccine, previous immunization history, the presence of any contraindications to immunization and current health status.

Before administration of VAXIGRIP®, health-care providers should inform the patient, parent or guardian of the benefits and risks of immunization, inquire about the recent health status of the patient and comply with any local requirements regarding information to be provided to the patient before immunization.

Hematologic

Because intramuscular injection can cause injection site hematoma, VAXIGRIP® should not be given to persons with any bleeding disorder, such as hemophilia or thrombocytopenia, or to persons on anticoagulant therapy unless the potential benefits clearly outweighs the risk of administration. If the decision is made to administer VAXIGRIP® in such persons, it should be given with caution, with steps taken to avoid the risk of bleeding and hematoma formation following injection.

Immune

If the vaccine is used in persons deficient in producing antibodies, whether due to genetic defect, immunodeficiency disease, or immunosuppressive therapy, the expected immune response may not be obtained. (9)

Respiratory

According to the National Advisory Committee on Immunization (NACI), persons who have experienced oculo-respiratory syndrome (ORS) symptoms including severe ORS consisting of non-lower respiratory symptoms (bilateral red eyes, cough, sore throat, hoarseness, facial swelling), may be safely reimmunized with influenza vaccine. (2)

However, NACI advises that expert review of the risks and benefits of vaccination should be sought for those who have previously experienced severe lower respiratory symptoms (wheeze, chest tightness, difficulty breathing) within 24 hours of influenza vaccination, an apparent allergic reaction to the vaccine, or any other symptoms (e.g., throat constriction, difficulty swallowing) that raise concern regarding the safety of re-immunization. This advice may be obtained from local medical officers of health or other experts in infectious disease, allergy/immunology, and/or public health. (2)

Special Populations

Pregnant Women

Animal reproduction studies have not been conducted with VAXIGRIP®. It is not known whether VAXIGRIP® can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity.

Data on the use of this vaccine in pregnant women are limited. VAXIGRIP® should be given to pregnant women only if clearly needed and following an assessment of the risks and benefits. (See INDICATIONS AND CLINICAL USE.)

NACI states that influenza vaccination is recommended for pregnant women who are characterized by any of the risk conditions (see INDICATIONS), in particular those who have chronic health conditions or who are close contacts of high-risk persons. Healthy women who will be pregnant during influenza season and who wish to avoid morbidity associated with influenza illness should be encouraged to be vaccinated during any trimester of pregnancy. (2)

Nursing Women

It is not known whether VAXIGRIP® is excreted in human milk. Caution must be exercised when VAXIGRIP® is administered to a nursing mother.

NACI states that influenza vaccination is recommended for breastfeeding women who are characterized by any of the conditions listed under recommended recipients (2) (see INDICATIONS AND CLINICAL USE). Influenza vaccine is safe for breastfeeding mothers.

ACIP states influenza vaccine is safe for mothers who are breastfeeding (3) (9) and their infants. (3) Breastfeeding does not adversely affect the immune response and is not a contraindication for vaccination. (3)

ADVERSE REACTIONS

Adverse Drug Reaction Overview

Adverse event information is derived from uncontrolled clinical trials and worldwide post-marketing experience.

Because VAXIGRIP® [Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion)] contains only non-infectious viruses, it cannot cause influenza. Respiratory disease after vaccination represents coincidental illness unrelated to influenza vaccination.

The most frequent side effect of influenza vaccination is soreness at the vaccination site. These local reactions generally are mild and rarely interfere with the person's ability to conduct usual daily activities. (3) Local redness, swelling, induration and bruising have also been reported. (13)

Fever, malaise, myalgia, arthralgia, lymphadenopathy, headache, shivering, sweating, fatigue (13) and other systemic symptoms can occur following vaccination with inactivated influenza vaccine and most often affect persons who have had no exposure to the influenza virus antigens in the vaccine (e.g., young children). (3) (14) These reactions usually disappear within 1-2 days without treatment.

Placebo-controlled trials suggest that among elderly persons and healthy young adults administration of split-virus influenza vaccine is not associated with higher rates of systemic symptoms (e.g., fever, malaise, myalgia and headache) when compared with placebo injections. (3) (15)

Prophylactic acetaminophen may decrease the frequency of some side effects in adults. (2) (16)

Clinical Trial Adverse Drug Reactions

Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

The strain composition of the influenza virus vaccines is subject to annual changes and respective clinical studies, including at least 50 adults 18-60 years of age and at least 50 elderly aged 60 years or older, are conducted as annual update requirements in Europe to assess the safety and immunogenicity of VAXIGRIP®. (17)

Five years of annual clinical safety data analysis were considered. (See Table 1.) (18) (19) (20) (21) (22)

A total of 779 vaccinees received an intramuscular injection of VAXIGRIP®. The most common reactions occurring after vaccine administration were local reactions at the injection site; mainly pain and erythema, asthenia and headache. Most of the adverse events were of mild to moderate intensity, usually occurring within one day of vaccination and resolving within 3 days.

Table 1 summarizes the frequencies (range across individual trials) of the solicited adverse events that were recorded within 3 days following the vaccination.

Data are categorized by age group and by MedDRA system organ class. An asterisk indicates that the adverse event was not reported in all studies.

Table 1: Adverse Events Within 3 Days After Vaccination of 779 Patients With VAXIGRIP®

Adverse Events	Adult 18-59 years (N = 393)	Elderly >60 years (N = 386)
<i>General Disorders and Administration Site Conditions</i>		
<i>Local reactions</i>		
Injection site pain	27 to 57%	11.5 to 23.7%
Injection site erythema	7.1 to 29.1%	7.1 to 29.9%
Injection site induration	4.5 to 17.3%	3.8 to 10.5%
Injection site edema	2.2 to 21.5%	5.8 to 14.5%*
Injection site bruising	1.1 to 7.4%*	1.9 to 4.5%*
Injection site pruritus	1.1 to 4.9%*	1.9 to 3%*
<i>Systemic complaints</i>		
Asthenia	4.3 to 14.8%	1.4 to 7.9%
Pyrexia (oral temperature >38°C)	1.2 to 1.4%*	1 to 1.5%*
Rigors	1.4 to 6.7%	1 to 3%*
Malaise	1.1 to 1.3%*	1.3%*
<i>Nervous system disorders</i>		
Headache	1.4 to 10%	2.9 to 6%*
<i>Musculoskeletal and connective tissue disorders</i>		
Arthralgia	1.4 to 3.8%*	1.5 to 2.6%*
Myalgia	1.1 to 8.9%	1.4 to 3%*
<i>Skin and subcutaneous tissue disorders</i>		
Sweating increased	1.4 to 4.9%	6%*

* Adverse event not reported in all studies

Post-Market Adverse Drug Reactions

Based on spontaneous reporting, the following additional adverse events have been reported during the commercial use of VAXIGRIP®. These events have been very rarely reported, however exact incidence cannot precisely be calculated. (23)

- Blood and lymphatic system disorders
Transient thrombocytopenia, lymphadenopathy.
- Immune system disorders
Allergic reactions: pruritus, rash erythematous urticaria, dyspnea, angioneurotic edema, or shock.
- Nervous system disorders
Paraesthesia, Guillain-Barré Syndrome (GBS), neuritis, neuralgia, convulsions, encephalomyelitis. (13) (24) (25)
- Vascular disorders
Vasculitis, (9) with transient renal involvement in certain cases. (26) (27)

Additional Adverse Reactions

The following adverse events not listed above have been reported with influenza vaccines:

During the 2000-2001 influenza season, PHAC received an increased number of reports of vaccine-associated symptoms and signs that were subsequently described as oculorespiratory syndrome (ORS). The case definition is as follows: the onset of bilateral red eyes and/or respiratory symptoms (cough, wheeze, chest tightness, difficulty breathing, difficulty swallowing, hoarseness or sore throat) and/or facial swelling occurring within 24 hours of influenza immunization. The pathophysiologic mechanism underlying ORS remains unknown, but it is considered distinct from IgE-mediated allergy. (2)

Since the 2000-2001 influenza season fewer ORS cases have been reported to PHAC. In the province of Quebec the rate of ORS per 100,000 doses distributed declined from 46.6 in 2000 to 34.2 and 20.6 in 2001 and 2002 respectively, to nine per 100,000 in 2003. Surveillance for all adverse events following immunization, including ORS, is ongoing. (2)

Approximately 5% to 34% of patients who have previously experienced ORS may have a recurrence attributable to the vaccine, but these episodes are usually milder than the original one, and vaccinees indicate willingness to be immunized in subsequent years. Persons who have a recurrence of ORS upon re-vaccination do not necessarily experience further episodes with future vaccinations. Data on clinically significant adverse events do not support the preference of one vaccine product over another when re-vaccinating those who have previously experienced ORS. (2)

Immediate – presumably allergic – reactions (e.g., hives, angioedema, allergic asthma, anaphylaxis, pruritus, erythematous rash, dyspnea) (3) (13) rarely occur after influenza vaccination. (3) These reactions probably result from hypersensitivity to certain vaccine components; the majority of reactions probably are caused by residual egg protein. (See CONTRAINDICATIONS.) Although current influenza vaccines contain only a limited quantity of egg protein, this protein can induce immediate hypersensitivity reactions among persons who have severe egg allergy. Persons who have had hives, or swelling of the lips or tongue, or have experienced acute respiratory distress or collapse after eating eggs should consult a physician for appropriate evaluation to help determine if vaccine should be administered. Persons who have documented immunoglobulin E (IgE)-mediated hypersensitivity to eggs - including those who have had occupational asthma or other allergic responses to egg protein - might also be at increased risk for allergic reactions to influenza vaccine and consultation with a physician such as an allergist, should be considered. (3) Protocols have been published for safely administering influenza vaccine to persons with egg allergies. (3) (28) (29)

Guillain-Barré Syndrome (GBS) occurred in adults in association with the 1976 swine influenza vaccine, and evidence favours the existence of a causal relation between the vaccine and GBS during that season. In an extensive review of studies since 1976, the United States (US) Institute of Medicine concluded that the evidence is inadequate to accept or reject a causal relation between GBS in adults and influenza vaccines administered after the swine influenza vaccine program in 1976. (2) (30)

In a Canadian study, the background incidence of GBS was estimated at 2.02 per 100,000 person-years in Ontario and 2.30 per 100,000 person-years in Quebec. A variety of infectious agents,

including *Campylobacter jejuni*, cytomegalovirus, Epstein-Barr virus, and *Mycoplasma pneumoniae* have been associated with GBS. It is not known whether influenza virus infection itself is associated with GBS. (2) Even if GBS were a true side effect of vaccination in the years after 1976, the estimated risk for GBS of approximately 1 additional case/1 million persons vaccinated is substantially less than the risk for severe influenza, which can be prevented by vaccination among all age groups, especially persons aged ≥ 65 years and those who have medical indications for influenza vaccination. The potential benefits of influenza vaccination in preventing serious illness, hospitalization and death substantially outweigh the possible risks for experiencing vaccine-associated GBS. (3) Whether influenza vaccination specifically might increase the risk for recurrence of GBS is unknown; therefore, NACI and the US Advisory Committee on Immunization Practices (ACIP) state it is prudent to avoid vaccinating persons who are not at high risk for severe influenza complications and who are known to have experienced GBS within 6 to 8 weeks after a previous influenza vaccination. (2) (3)

The average case-fatality ratio in the US for GBS is 6% and increases with age. (3) No evidence indicates that the case-fatality ratio for GBS differs among vaccinated persons and those not vaccinated. (3)

Influenza vaccine is not known to predispose vaccine recipients to Reye syndrome. (2)

Neurological disorders temporally associated with influenza vaccination such as encephalopathy (with or without permanent neurological - motor and/or sensory - deficit and/or intellectual impairment), optic neuritis, facial paralysis, labyrinthitis, brachial plexus neuropathy, paresthesia and convulsion have been reported. However, no cause-and-effect relationships have been established. (24) Encephalomyelitis (25) and neuritis have also been reported. (13)

Physicians, nurses and pharmacists should report any adverse occurrences temporally related to the administration of the product in accordance with local requirements and to the Global Pharmacovigilance Department, Sanofi Pasteur Limited, 1755 Steeles Avenue West, Toronto, ON, M2R 3T4, Canada. 1-888-621-1146 (phone) or 416-667-2435 (fax).

DRUG INTERACTIONS

Although influenza vaccination can inhibit the clearance of warfarin, theophylline and phenytoin, (31) clinical studies have not shown any adverse effects attributable to these drugs in persons receiving influenza vaccine. (2)

If the vaccine is used in persons deficient in producing antibodies due to immunosuppressive therapy, the expected immune response may not be obtained.

Simultaneous Administration of Other Vaccines

Adult target groups for influenza and pneumococcal polysaccharide vaccination overlap considerably. Health-care providers should take the opportunity to vaccinate eligible persons against pneumococcal disease when influenza vaccine is given. (9) Clinical studies show that influenza vaccine may be administered with pneumococcal vaccine using separate syringes at different sites. (32) (33)

No studies regarding the simultaneous administration of inactivated influenza vaccine and other childhood vaccines have been conducted. According to NACI, inactivated vaccines usually do not interfere with the immune response to other inactivated or live vaccines (9) and influenza vaccine may be given at the same time as other vaccines, provided different sites and administration sets (needle and syringe) are used. (2) (9)

VAXIGRIP® [Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion)] must not be mixed in the same syringe with other parenterals.

DOSAGE AND ADMINISTRATION

Recommended Dose

The recommended dosage schedule is presented in Table 2.

Table 2: Recommended Influenza Vaccine Dosage, by age, 2005-2006

Age Group	Dose	No. of Doses
6 to 35 months	0.25 mL	1 or 2*
3 to 8 years	0.5 mL	1 or 2*
≥9 years	0.5 mL	1

* Previously unvaccinated children < 9 years of age require 2 doses of influenza vaccine with an interval of 4 weeks. The second dose is not needed if the child received one or more doses of vaccine during a previous influenza season. (2)

Inspect for extraneous particulate matter and/or discoloration before use. If these conditions exist, the product should not be administered.

For information on vaccine administration, see the current edition of the Canadian Immunization Guide or visit the Health Canada website.

Administer the vaccine **intramuscularly**. The preferred site is into the deltoid muscle, in adults and children >1 year of age. The preferred site for infants and young children (<1 year of age) is the anterolateral aspect of the mid-thigh (vastus lateralis muscle).

VAXIGRIP® [Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion)] is supplied in packages containing either: one pre-filled single dose (0.5 mL) syringe with a fixed needle, one pre-filled single-dose (0.25 mL) syringe with a fixed needle, a pre-filled single-dose (0.5 mL) syringe co-packaged with two needles, a multidose vial, or a single-dose ampoule.

SHAKE THE PRE-FILLED SYRINGE WELL to uniformly distribute the suspension before administration.

If using a pre-filled syringe with two needles, select a needle of appropriate length to ensure that the vaccine will be delivered intramuscularly. Remove the tip cap from the syringe, take the chosen needle from the blister pack and fix to the tip of the pre-filled syringe.

For children, when a single dose 0.5 mL syringe is to be used for administration of a 0.25 mL dose, push the plunger exactly to the edge of the mark so that half of the volume is eliminated. The remaining volume should be injected.

If using a multidose vial, SHAKE THE VIAL WELL to uniformly distribute the suspension before withdrawing each dose. When administering a dose from a stoppered vial, do not remove either the stopper or the metal seal holding it in place. Aseptic technique must be used for withdrawal of each dose. (See WARNINGS AND PRECAUTIONS.)

If using an ampoule, SHAKE THE AMPOULE WELL to uniformly distribute the suspension before withdrawing each dose. Before withdrawing a dose from an ampoule, tap the container first to ensure that any vaccine in the ampoule neck falls to the lower portion of the ampoule. Once the ampoule has been opened, any of its contents not used immediately should be discarded. Aseptic technique must be used for withdrawal of each dose. (See WARNINGS AND PRECAUTIONS.)

Do not inject intravenously.

Needles should not be recapped but should be disposed of according to biohazard waste guidelines.

Give the patient a permanent personal immunization record. In addition, it is essential that the physician or nurse record the immunization history in the permanent medical record of each patient. This permanent office record should contain the name of the vaccine, date given, dose, manufacturer and lot number.

OVERDOSAGE

Not applicable.

ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action

The inoculation of antigen prepared from inactivated influenza virus stimulates the production of specific antibodies. Protection is afforded only against those strains of virus from which the vaccine is prepared or closely related strains.

Immunity to the surface antigens, especially to the hemagglutinin, reduces the likelihood of infection and lessens the severity of disease if infection occurs. Antibody against one influenza virus type or subtype confers limited or no protection against another. Furthermore, antibody to one antigenic variant of influenza virus might not protect against a new antigenic variant of the same type or subtype. Frequent development of antigenic variants through antigenic drift is the virologic basis for seasonal epidemics and the reason for the usual incorporation of one or more new strains in each year's influenza vaccine. (3)

Each year's influenza vaccine contains three virus strains (usually two type A, and one type B) representing the influenza viruses that are believed likely to circulate in the coming winter. (1) (9) The antigenic characteristics of current and emerging influenza virus strains provide the basis for selecting the strains included in each year's vaccine. (1) (9)

Pharmacodynamics

Seroprotection is generally obtained within 2 to 3 weeks.

Pharmacokinetics

No pharmacokinetic studies have been performed.

Duration of Effect

The duration of postvaccinal immunity varies and is usually 6-12 months. (34)

STORAGE AND STABILITY

Store at 2° to 8°C (35° to 46°F). DO NOT FREEZE. Discard product if exposed to freezing.

Protect from light. Do not use vaccine after expiration date.

SPECIAL HANDLING INSTRUCTIONS

A vial of VAXIGRIP® [Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion)] which has been entered and in use for 7 days should be discarded.

DOSAGE FORMS, COMPOSITION AND PACKAGING

Dosage Forms

Vial	1 x 5 mL (Multidose)
Pre-filled Syringe	1 x 0.25 mL (Single Dose) with an attached (25G, 16 mm) needle
Pre-filled Syringe	1 x 0.5 mL (Single Dose) with an attached (25G, 16 mm) needle
Pre-filled Syringe	1 x 0.5 mL (Single Dose) co-packaged with two 25G needles of different lengths (16 mm and 25 mm)
Ampoule	1 x 0.5 mL (Single Dose)
Ampoule	5 x 0.5 mL (Single Dose)

The plunger stopper of the pre-filled syringe with the attached (25G, 16 mm) needle does not contain dry natural latex rubber. The plunger stopper of the pre-filled syringe co-packaged with two 25G needles of different lengths (16 mm and 25 mm) does not contain dry natural latex rubber. The vial stopper does not contain dry natural latex rubber.

Composition

For the 2006/2007 season each 0.5 mL dose of VAXIGRIP® [Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion)] contains:

- 15 µg HA - A/New Caledonia/20/99 (H1N1)-like strain (A/New Caledonia/20/99 IVR-116),
- 15 µg HA - A/Wisconsin/67/2005 (H3N2)-like strain (A/Wisconsin/67/2005 NYMC X-161 or X-161B),
- 15 µg HA - B/Malaysia/2506/2004-like strain (B/Malaysia/2506/2004).

Other ingredients: ≤30 µg formaldehyde, up to 0.5 mL sodium phosphate-buffered, isotonic sodium chloride solution. 2 µg thimerosal*, Triton® X-100, trace amounts of sucrose and neomycin.

* (added as a preservative in multidose presentation only)

For the 2006/2007 season each 0.25 mL dose of VAXIGRIP® contains:

- 7.5 µg HA - A/New Caledonia/20/99 (H1N1)-like strain (A/New Caledonia/20/99 IVR-116),
- 7.5 µg HA - A/Wisconsin/67/2005 (H3N2)-like strain (A/Wisconsin/67/2005 NYMC X-161 or X-161B),
- 7.5 µg HA - B/Malaysia/2506/2004-like strain (B/Malaysia/2506/2004).

Other ingredients: ≤15 µg formaldehyde, up to 0.25 mL sodium phosphate-buffered, isotonic sodium chloride solution, 1 µg thimerosal*, Triton® X-100, trace amounts of sucrose and neomycin.

* (added as a preservative in multidose presentation only)

After shaking, VAXIGRIP® is slightly whitish and opalescent in colour.

Full product monograph available on request.

Visit us at www.sanofipasteur.ca

Vaccine Information Service: 1-888-621-1146 or 416-667-2779

Product information as of August 2006.

Manufactured by:

Sanofi Pasteur SA

Lyon, France

Distributed by:

Sanofi Pasteur Limited

Toronto, Ontario, Canada

R11-0806 Canada

PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

Proper name: Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion)

For the 2006/2007 season each 0.5 mL dose of VAXIGRIP® contains:

15 µg HA - A/New Caledonia/20/99 (H1N1)-like strain (A/New Caledonia/20/99 IVR-116),

15 µg HA - A/Wisconsin/67/2005 (H3N2)-like strain (A/Wisconsin/67/2005 NYMC X-161 or X-161B),

15 µg HA - B/Malaysia/2506/2004-like strain (B/Malaysia/2506/2004).

Other ingredients: ≤30 µg formaldehyde, up to 0.5 mL sodium phosphate-buffered, isotonic sodium chloride solution. 2 µg thimerosal*, Triton® X-100, trace amounts of sucrose and neomycin.

* (added as a preservative in multidose presentation only)

For the 2006/2007 season each 0.25 mL dose of VAXIGRIP® contains:

7.5 µg HA - A/New Caledonia/20/99 (H1N1)-like strain (A/New Caledonia/20/99 IVR-116),

7.5 µg HA - A/Wisconsin/67/2005 (H3N2)-like strain (A/Wisconsin/67/2005 NYMC X-161 or X-161B),

7.5 µg HA - B/Malaysia/2506/2004-like strain (B/Malaysia/2506/2004).

Other ingredients: ≤15 µg formaldehyde, up to 0.25 mL sodium phosphate-buffered, isotonic sodium chloride solution, 1 µg thimerosal*, Triton® X-100, trace amounts of sucrose and neomycin.

* (added as a preservative in multidose presentation only)

The type and amount of viral antigens contained in VAXIGRIP® conform to the current requirements of the World Health Organization (WHO). (1)

Product Characteristics

VAXIGRIP® for intramuscular use, is a sterile suspension prepared from influenza viruses cultivated in embryo containing hens' eggs. Each of the strains is separately inoculated into the allantoic cavity of chicken embryos aged 11 days with neomycin solution equivalent to 0.5 mg per egg. Following the allantoic fluid is collected and clarified, and the viruses are concentrated, then purified by zonal centrifugation using a sucrose density gradient. Subsequent stages consist of treatment with octoxinol-9 (Triton® X-100) to obtain split antigens, then inactivation using formaldehyde solution. The final vaccine is obtained by mixing the three strains in a buffer. Thimerosal is then added for the multidose presentation only.

After shaking, VAXIGRIP® is slightly whitish and opalescent in colour.

CLINICAL TRIALS

Study Demographics and Trial Design

The immunogenicity of VAXIGRIP® [Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion)] has been demonstrated in clinical trials in adults (age 18-60 years), elderly (age >60 years), and young children (age 6-36 months and 3-10 years). The strain composition of influenza virus vaccines is subject to annual changes, and annual studies in adults to verify the immunogenicity are performed. (See Table 3.) In the annual studies (13) and in study 3 (35), a single dose of VAXIGRIP® was given and antibody titres were assessed immediately before vaccination and 21 days later. In study 2 (36), antibody titres were assessed immediately before the first dose and 27-33 days following the second vaccine dose.

Table 3: Summary of Patient Demographics for Clinical Trials

Study #	Trial design	Dosage, route of administration and duration	Study subjects (n=number)	Mean age (Range)	Gender
Annual Study (13)	Open	0.5 mL IM	>50 >50	18-60 years >60 years	--
Study 2 (13) (36)	Open	0.25 mL IM; 2 doses 1 month apart	65	6 months to 3 years	Male 37 Female 28
Study 3 (35)	Open	0.5 mL	42 (12 had received prior influenza vaccination)	8-10 years	Male 19 Female 23

Study Results

The efficacy of influenza vaccine is assessed using a surrogate for protection defined as the immune response elicited by the vaccine (hemagglutination inhibition). In the annual studies, the serologic responses of both adult age groups to all antigens must meet the assessment criteria as defined in the European Requirements for Influenza Vaccines (i.e., for subjects 18-60 years – at least one of seroconversion or significant increase in antihemagglutinin antibody titre in >40%, mean GMT increase >2.5, proportion of subjects achieving HI (hemagglutination inhibition) titre or seroprotection >70%, and for subjects >60 years at least one of seroconversion or significant increase in antihemagglutinin antibody titre in >30%, mean GMT increase >2.0, proportion of subjects achieving HI titre >60%.) (17) Elderly subjects generally respond less well to influenza vaccines than young healthy adults, and those with chronic debilitating medical conditions generally respond less well than healthy subjects of similar age. (37)

The results in children met the criteria defined for young adults; no criteria for children have been set.

DETAILED PHARMACOLOGY

Influenza A and B are the two types of influenza viruses that cause epidemic human disease. Influenza A viruses are further categorized into subtypes on the basis of two surface antigens: hemagglutinin (H) and neuraminidase (N). Influenza B viruses are not categorized into subtypes.(3) Since 1977, influenza A (H1N1) viruses, influenza A (H3N2) viruses and influenza B viruses have been in global circulation. (3) Influenza A (H1N2) has been circulating widely since 2001. (3) Because circulating influenza A (H1N2) viruses are a reassortant of influenza A

(H1N1) and (H3N2) viruses, antibody directed against influenza A (H1N1) and (H3N2) vaccine strains will provide protection against circulating influenza A (H1N2) viruses. (3)

In the tropics, influenza can occur throughout the year. In the southern hemisphere, peak activity occurs from April through September.

Uncomplicated influenza illness is characterized by the abrupt onset of constitutional and respiratory signs and symptoms (e.g., fever, myalgia, headache, malaise, nonproductive cough, sore throat and rhinitis). Illness typically resolves after a limited number of days for the majority of persons, although cough and malaise can persist for two or more weeks. Among certain persons, influenza can exacerbate underlying medical conditions (e.g., pulmonary or cardiac disease), lead to secondary bacterial pneumonia or primary influenza viral pneumonia, or occur as part of a coinfection with other viral or bacterial pathogens. (3) The spectrum of influenza in children ranges from asymptomatic infection to influenza illness with or without complications. In addition to febrile upper respiratory tract infection, common clinical presentations of influenza in children include lower respiratory tract infection (croup, bronchiolitis, primary viral, or secondary bacterial pneumonia), otitis media, diarrheal illness, and febrile seizures. Influenza infection has also been associated with encephalopathy, transverse myelitis, Reye syndrome, myositis, myocarditis, and pericarditis. (3) The risks of complications, hospitalizations and deaths from influenza are higher among persons 65 years of age or older, young children and persons of any age with some underlying health conditions than among healthy older children and younger adults. (3)

Vaccination is recognized as the single most effective way of preventing or attenuating influenza for those at high risk of serious illness or death from influenza infection and related complications. (2)

The inoculation of antigen prepared from inactivated influenza virus stimulates the production of specific antibodies. Protection is afforded only against those strains of virus from which the vaccine is prepared or closely related strains.

Immunity to the surface antigens, especially to the hemagglutinin, reduces the likelihood of infection and severity of disease if infection occurs. Antibody against one influenza virus type or subtype confers limited or no protection against another. Furthermore, antibody to one antigenic variant of influenza virus might not protect against a new antigenic variant of the same type or subtype. Frequent development of antigenic variants through antigenic drift is the virologic basis for seasonal epidemics and the reason for the usual incorporation of one or more new strains in each year's influenza vaccine. (3)

Each year's influenza vaccine contains three virus strains (usually two type A and one type B) representing the influenza viruses that are believed likely to circulate in the coming winter. (1) (9) The antigenic characteristics of current and emerging influenza virus strains provide the basis for selecting the strains included in each year's vaccine. (1) (9)

The majority of vaccinated children and young adults develop high post-vaccination hemagglutination inhibition antibody titres. These antibody titres are protective against illness caused by strains similar to those in the vaccine. Older persons and persons with certain chronic diseases might develop lower post-vaccination antibody titres than healthy young adults and thus can remain susceptible to influenza-related upper respiratory tract infection. The vaccine can also be effective in preventing secondary complications and reducing the risk for influenza-related

hospitalization and death among adults 65 years and older with and without high-risk medical conditions (e.g., heart disease and diabetes). (3)

The effectiveness of influenza vaccine varies depending upon the age and immunocompetence of the vaccine recipient, the degree of similarity between the virus strain included and the characteristics of the strain of circulating virus during the influenza season. With a good match, influenza vaccination has been shown to prevent laboratory-confirmed influenza illness in approximately 70% or more of healthy individuals. (39) (2) In the elderly, vaccination against influenza is associated with reductions in the risk of hospitalization for heart disease, cerebrovascular disease, and pneumonia or influenza as well as the risk of death from all causes during influenza season. (40) In older persons living in residential facilities influenza vaccine prevents pneumonia, hospital admission, death from pneumonia (vaccine effectiveness 42% to 46%), and all-cause mortality (vaccine effectiveness 60%) (2) (40)

Children aged as young as 6 months can develop protective levels of antibody after influenza vaccination, although the antibody response among children at high risk of influenza-related complications might be lower than among healthy children. In a randomized study among children aged 1 - 15 years, inactivated influenza vaccine was 77% - 91% effective against influenza respiratory illness. (3) Vaccination of health-care workers has been associated with reduced work absenteeism (3) (41) and decreased deaths among nursing home patients. (3) (42)

Vaccination is associated with reductions in influenza-related respiratory illness and physician visits among all age groups, hospitalization and death among persons at high risk, otitis media among children and work absenteeism among adults. (3) (43)

Although the current influenza vaccine can contain one or more of the antigens administered in previous years, annual vaccination using the current vaccine is necessary because immunity declines in the year following vaccination.

TOXICOLOGY

Data in animals revealed no unexpected findings and no target organ toxicity. (44) (45) (46)

REFERENCE LIST

- 1 Recommended composition of influenza virus vaccines for use in the 2006-2007 influenza season. *Wkly Epid Rec* 2006;81:82-6.
- 2 National Advisory Committee on Immunization (NACI). Statement on influenza vaccination for the 2006-2007 season. *CCDR* 2006;32(ACS-7):1-27.
- 3 CDC. Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 2005;54(RR-8):1-40.
- 4 Fedson DS, et al. Clinical effectiveness of influenza vaccination in Manitoba. *JAMA* 1993;270:1956-61.
- 5 Miller J, et al. Influenza A outbreak on a cruise ship. *CCDR* 1998;24(2):9-10.
- 6 Health Canada. Prevention and control of occupational infection in health-care. An Infection Control Guideline. *CCDR* 2002;28S1:184.
- 7 WHO. WHO interim recommendations for the protection of persons involved in the mass slaughter of animals potentially infected with highly pathogenic avian influenza viruses. 2004:1-2.
- 8 Health Canada. Statement on travel, influenza and prevention. *CCDR* 2005;31(ACS-2):1-8.
- 9 National Advisory Committee on Immunization: Canadian Immunization Guide, Sixth ed. Her Majesty the Queen in Right of Canada represented by the Minister of Public Works and Government Services Canada; 2002. p. 4,7,14-8,20-6,31-2,120-1,125.
- 10 Sanofi Pasteur. Data on file. A/146MRP/3372/SPIIC1/09.97/01.0. Part IIC: Production and control of starting materials. 1 - Active substance. Geode ref. 3372 September 1997.
- 11 National Advisory Committee on Immunization (NACI). Statement on thimerosal. *CCDR* 2003;29(ACS-1):1-12.
- 12 Plott RT, et al. Iatrogenic contamination of multidose vials in simulated use. *Arch Dermatol* 1990;126:1441-4.
- 13 Data on file at Sanofi Pasteur SA.
- 14 Scheifele DW, et al. Evaluation of adverse events after influenza vaccination in hospital personnel. *CMAJ* 1990;142:127-30.
- 15 Nichol KL. Side effects associated with influenza vaccination in healthy working adults: a randomized, placebo-controlled trial. *Arch Intern Med* 1996;156:1546-50.
- 16 Aoki FY, et al. Effects of acetaminophen on adverse effects of influenza vaccination in health-care workers. *CMAJ* 1993;149(10):1425-30.
- 17 European Agency for the Evaluation of Medicinal Products (EMA). Note for guidance on harmonisation of requirements for influenza vaccines. CPMP/BWP/214/96. 1997:1-18.
- 18 Sanofi Pasteur. Data on file. A/314/IVB1/06.02/01.0 - VAXIGRIP - Part IV Clinical Documentation - IVB1 Clinical trial: Immunogenicity and Safety of the influenza vaccine (split virion) - 2002/2003 formulation. Trial GRT 43. June 2002.
- 19 Sanofi Pasteur. Data on file. A/146MRP/314/5955/IVB1/06.01/01.0: VAXIGRIP - Part IIV Clinical Documentation - IVB1 Clinical Trial: Immunogenicity and Safety of the

- inactivated influenza vaccine (split virion) - 2001/2002 formulation. Trial GRT 16201. June 2001.
- 20 Sanofi Pasteur. Data on file. A/146MRP/5202-5203-5205/IVB1/06.00/01.0: Mutagrip - Part IV Clinical Documentation - IVB1 Clinical Trial: Immunogenicity and Safety of the inactivated influenza vaccine (split virion) - 2000/2001 formulation. Trial GRT 15200. June 2000.
- 21 Sanofi Pasteur. Data on file. A/146MRP/4810-4816-4817/IVB1/07.99/01.0: VAXIGRIP - Part IV Clinical Documentation - IVB1 Clinical Trial: Immunogenicity and Safety of the inactivated influenza vaccine (split virion) - 1999/2000 formulation. Trial GRT 14299. July 1999.
- 22 Sanofi Pasteur. Data on file. A/146 IVB1. Part IV Clinical Documentation - IVB1 Clinical Trial: Immunogenicity and Safety of the inactivated influenza virus (split virion) - 1998/1999 formulation. Trial GRT 09298. July 1998.
- 23 Report from CIOMS working group III. Chapter 5: Good Safety Information Practices. In: CIOMS editors, Guideline for preparing Core Clinical Safety Information on drugs. Geneva: CIOMS. 1995:30-8.
- 24 Stratton K, et al. editors. Immunization Safety Review: Influenza vaccines and neurological complications. Washington, DC: The National Academies Press; 2004. p. 145.
- 25 Guerrero IC, et al. No increased meningoencephalitis after influenza vaccine. *N Engl J Med* 1979;300(10):565.
- 26 Bedard PM, Gascon G. Fatal outcome of systemic vasculitis following influenza vaccination. *Can J Allergy Clin Immun* 1999;4:405-6.
- 27 Mader R, et al. Systemic vasculitis following influenza vaccination - report of three cases and literature review. *J Rheumatol* 1993;20:1429-31.
- 28 James JM, et al. Safe administration of influenza vaccine to patients with egg allergy. *J Pediatr* 1998;133:624-8.
- 29 Murphy KR, et al. Safe administration of influenza vaccine in asthmatic children hypersensitive to egg proteins. *J Pediatr* 1985;106:931-3.
- 30 Institute of Medicine. Immunization safety review: influenza vaccines and neurological complications. URL: <<http://www.iom.edu/report.asp?id=15626>>
- 31 Kilbourne ED, et al. Inactivated Influenza Vaccines. In: Plotkin SA and Orenstein WA, editors. *Vaccines*. 3rd ed. Philadelphia, PA: W.B. Saunders Company; 1999. p. 543.
- 32 Grilli G, et al. Simultaneous influenza and pneumococcal vaccination in elderly individuals. *Eur J Epidemiol*. 1997;13(3):287-291.
- 33 Honkanen PO, et al. The impact of vaccination strategy and methods of information on influenza and pneumococcal vaccination coverage in the elderly population. *Vaccine*. 1997;15(3):317-20.
- 34 Sanofi Pasteur. Data on file. A/146MRP/3523/SPI C3/09.97/01.0: Parti IC3 - Expert Report on the clinical documentation. Geode Ref 3523. September 1997.
- 35 Lina B, et al. A Triton X-100-split virion influenza vaccine is safe and fulfills the committee for proprietary medicinal products (CPMP) recommendations for the European community for immunogenicity, in children, adults and the elderly. *Biologicals* 2000;28:95-103.

- 36 Gonzalez M, et al. Safety and immunogenicity of a paediatric presentation of an influenza vaccine. *Arch Dis Child* 2000;83:488-91.
- 37 Fukuda K, et al. Inactivated Influenza Vaccines. In: Plotkin SA and Orenstein WA, editors. *Vaccines*. 4th ed. Philadelphia, PA: Elsevier Inc.; 2004. p. 358.
- 38 Nichol KL, et al. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. *N Engl J Med* 1994;331:778-84.
- 39 Langley JM, Faughnan ME. Prevention of influenza in the general population. *CMAJ* 2004;171(10):1213-22.
- 40 Nichol KL, et al. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. *N Engl J Med* 2003;348:1322-32.
- 41 Wilde JA, et al. Effectiveness of influenza vaccine in health-care professionals. *JAMA* 1999;281:908-13.
- 42 Carman WF, et al. Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial. *Lancet* 2000;355:93-7.
- 43 Ruben FL. Inactivated influenza virus vaccines in children. *CID* 2004;38:678-88.
- 44 Sanofi Pasteur. Data on file. CIT/Study 13498, TSR/VAXIGRIP/PCPP/Pasteur Merieux. 1996.
- 45 Sanofi Pasteur. Data on file. CIT/STudy 15197, TAL/Flu DC Chol and DC Chol/Pasteur Merieux Connaught. 1997.
- 46 Sanofi Pasteur. Data on file. CIT/STudy AA17119. Repeated dose toxicity and local tolerance in rabbits by intramuscular route. 2004.

Full product monograph available on request.

Visit us at www.sanofipasteur.ca

Vaccine Information Service: 1-888-621-1146 or 416-667-2779

Product information as of August 2006.

Manufactured by:
Sanofi Pasteur SA
Lyon, France

Distributed by:
Sanofi Pasteur Limited
Toronto, Ontario, Canada

R11-0806 Canada

IMPORTANT: PLEASE READ

PART III: CONSUMER INFORMATION

VAXIGRIP®

Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion)

This leaflet is part III of a three-part "Product Monograph" published when VAXIGRIP® was approved for sale in Canada. It provides important information about the product for Consumers. This leaflet is a summary and it does not tell you everything about VAXIGRIP®. Contact your doctor, nurse or pharmacist if you have any questions about the vaccine.

ABOUT THIS MEDICATION

VAXIGRIP® is a vaccine used to prevent influenza. Influenza (or flu) is an infection caused by the influenza virus.

This vaccine may be given to adults and children 6 months of age and older.

Flu symptoms can include fever, headache, muscle pain, runny nose, sore throat, extreme tiredness and cough. Some people get much sicker.

The influenza virus spreads when a person who has the flu coughs or sneezes into the air. Small droplets of the flu virus stay in the air for a short time then fall onto surfaces nearby. You can get the flu by:

- breathing in these droplets through your nose or mouth.
- the droplets landing directly on your eyes.
- touching the hands of a person who has the flu and then touching your eyes, nose or mouth.
- touching surfaces that have been contaminated with flu virus and then touching your eyes, nose or mouth.

What it does:

VAXIGRIP® causes your body to produce its own protection against influenza virus. After you get a flu shot, your immune system produces antibodies against the strains of virus that are in the vaccine. The antibodies are effective for six to 12 months. When you are exposed to the virus, the antibodies will help to keep you from getting sick. If you do get the flu, you may not be as sick.

When it should not be used:

VAXIGRIP® should not be used in the following situations:

Do not use VAXIGRIP® for infants under 6 months of age.

Do not give VAXIGRIP® to anyone who has ever had an allergic reaction to:

- egg or egg products
- chicken protein
- any component of VAXIGRIP® or its container.

Do not give VAXIGRIP® to a person who has a fever or serious illness. Wait until the person is better before giving the flu shot. A person who has a mild illness (such as a mild cold) may have the flu shot. Ask your doctor, nurse or pharmacist for advice.

What the medicinal ingredient is:

Each 0.5 mL dose of VAXIGRIP® contains killed split viruses from three strains of influenza virus for the 2006-2007 season. The viruses in VAXIGRIP® are:

- **A/New Caledonia/20/99 (H1N1)-like strain (A/New Caledonia/20/99 IVR-116),**
- **A/Wisconsin/67/2005 (H3N2)-like strain (A/Wisconsin/67/2005 NYMC X-161 or X-161B)**
- **B/Malaysia/2506/2004-like strain (B/Malaysia/2506/2004)**

What the important nonmedicinal ingredients are:

Thimerosal (only in the multidose vial), neomycin, formaldehyde, sodium phosphate-buffered, isotonic sodium chloride solution, Triton® X-100 and sucrose.

What dosage forms it comes in:

Individual doses in a prefilled syringe (needle) or a vial that contains enough vaccine for many doses.

WARNINGS AND PRECAUTIONS

VAXIGRIP® will only protect against the strains of flu virus contained in the vaccine or those that are closely related.

VAXIGRIP® will not protect against any other strains of flu virus.

If you have any of the following conditions, talk to your doctor, nurse or pharmacist BEFORE you use VAXIGRIP®:

Persons who have diseases of the immune system or who are having treatment that affects the immune system. The vaccine may provide you with a lower level of protection than it does for people with healthy immune systems.

Persons who have coagulation disorders or are on anticoagulant therapy. Tell the person giving you the injection about your condition. There is a risk of excessive bleeding where you get the injection if it is not done carefully.

Pregnant or breast-feeding women. It is important that you understand the risks and benefits of vaccination. VAXIGRIP® should be given to a pregnant or nursing woman only if it is clearly needed. Tell the

person giving you the injection if you are pregnant or breast-feeding.

Persons with an allergy to any component of the vaccine or the container.

INTERACTIONS WITH THIS MEDICATION

VAXIGRIP® must not be mixed with other vaccines or medicinal products in the same syringe.

PROPER USE OF THIS MEDICATION

Usual dose:

For children 6 to 35 months - recommended dose is 0.25 mL.

For persons 3 years or older - recommended dose is 0.5 mL.

Children under 9 years of age that have not received a previous vaccination - 2 doses are required 4 weeks apart. The second dose is not needed if the child received one or more doses of influenza vaccine in a previous season.

For adults and children older than 1 year, inject the vaccine into the deltoid (shoulder) muscle.

For infants and children less than 1 year inject the vaccine into the mid-thigh muscle.

Overdose:

Not applicable to this vaccine.

Missed Dose:

If a child's second dose is missed, it can be given at any time.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

A vaccine, like any medicine, may cause serious problems, such as severe allergic reactions. The risk of VAXIGRIP® causing serious harm is extremely small. The small risks associated with VAXIGRIP® are much less than the risks associated with getting the disease against which it protects.

The flu vaccine cannot cause influenza because it does not contain any live virus. The most common side effect is soreness where you got the injection. It may last a couple of days. You might also notice fever, fatigue and muscle aches within 6 to 12 hours after your shot. These side effects may last a day or two.

Severe allergic reactions to the flu shots are very rare. A very rare but possible side effect of influenza vaccination is Guillain-Barré Syndrome (GBS). This is an autoimmune disease that attacks the nervous system. GBS causes weakness and abnormal sensations. Most patients recover fully. Your chance of developing GBS as a result of a flu shot is one in a million.

This is not a complete list of side effects. Talk to your doctor or nurse before receiving VAXIGRIP®.

Tell your doctor, nurse or pharmacist as soon as possible if you do not feel well after having VAXIGRIP®.

For any unexpected effects after having VAXIGRIP®, contact your doctor, nurse or pharmacist.

HOW TO STORE IT

Store in a refrigerator at 2° to 8°C (35° to 46°F). DO NOT FREEZE. Protect from light. Discard product if it has been exposed to freezing.

Do not use vaccine after expiration date.

Discard open vials of VAXIGRIP® after 7 days.

Keep VAXIGRIP® out of children's reach.

REPORTED SUSPECTED SIDE EFFECTS

To monitor vaccine safety, Health Canada collects information on serious and unexpected effects of vaccine(s). If you suspect you have had a serious or unexpected reaction to this vaccine you may notify

Health Canada by:

telephone: 613-952-6339

fax: 613-946-0224

By email: VAAES@phac-aspc.gc.ca

By regular mail:

The Vaccine Safety Unit,
Immunization & Respiratory Infections Division,
Centre for Infectious Disease Prevention & Control,
Public Health Agency of Canada,
PL 0602C Bldg #6, Tunney's Pasture,
Ottawa, Ontario,
K1A 0K9

NOTE: Before contacting Health Canada, you should contact your physician, nurse or pharmacist.

MORE INFORMATION

This document plus the full product monograph, prepared for health professionals can be found at: <http://www.sanofipasteur.ca> or by contacting the sponsor, Sanofi Pasteur Limited, 1755 Steeles Avenue West, Toronto, Ontario, M2R 3T4.

Phone: 1-888-621-1146 or 416-667-2779.

This leaflet was prepared by Sanofi Pasteur Limited.

Last revised: August 2006

R11-0806 Canada